Clinical Trials
31 trialsNCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00114179 2020-10-30
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00602602 2020-04-27
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02620800 2019-10-22
FABLOx
Celgene
Phase 1 Completed
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed
NCT00460174 2018-10-29
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
Northwestern University
Phase 2 Completed
NCT00557492 2018-09-25
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
University of Pittsburgh
Phase 2 Completed
NCT00365144 2018-01-19
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
University of California, San Francisco
Phase 2 Completed
NCT00366457 2017-05-15
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00112528 2016-12-13
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00260364 2016-10-14
TARGET
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT00614653 2016-08-01
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00100815 2015-12-24
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00417976 2015-10-01
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00925769 2015-08-07
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00735306 2015-06-18
TART
Duke University
Phase 1 Completed
NCT01214720 2014-08-13
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091026 2014-05-15
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00088894 2013-06-05
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00028834 2013-01-24
Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00126633 2012-09-17
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
University of California, San Francisco
Phase 2 Completed
NCT00047710 2012-08-01
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00336648 2012-07-30
Preop Chemoradiation Resectable Pancreas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00222469 2008-07-09
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
University of Oklahoma
Phase 2 Completed